Literature DB >> 29696750

Angelman syndrome in adolescence and adulthood: A retrospective chart review of 53 cases.

Ankita Prasad1, Olivia Grocott1, Kimberly Parkin1, Anna Larson1, Ronald L Thibert1.   

Abstract

Angelman syndrome is a neurogenetic disorder with varying clinical presentations and symptoms as the individual ages. The goal of this study was to characterize changes over time in the natural history of this syndrome in a large population. We reviewed the medical records of the 53 patients who were born prior to 2000 and seen at the Angelman Syndrome Clinic at Massachusetts General Hospital to assess neurological, sleep, behavioral, gastrointestinal, orthopedic, and ophthalmologic functioning. The average age of this cohort was 24 years. Active seizures were present in 35%, nonepileptic myoclonus in 42%, and clinically significant tremors in 55%. Anxiety was present in 57%, increasing to 71% in those ages 26-43 years. In terms of sleep, 56% reported 8 hr of sleep or more, although 43% reported frequent nocturnal awakenings. Gastrointestinal issues remain problematic with 81% having constipation and 53% gastroesophageal reflux. The majority lived in a parent's home and remained independently mobile, though scoliosis was reportedly present in 30%, and 20% had reported low bone density/osteoporosis. The results of this study suggest that the prevalence of active seizures may decrease in adulthood but that the prevalence of movement disorders such as tremor and nonepileptic myoclonus may increase. Anxiety increases significantly as individuals age while defiant behaviors appear to decrease. Sleep dysfunction typically improves as compared to childhood but remains a significant issue for many adults. Other areas that require monitoring into adulthood include gastrointestinal dysfunction, and orthopedic/mobility issues, such as reported scoliosis and bone density, and ophthalmologic disorders.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  Angelman syndrome; adolescents; adults; anxiety; myoclonus; seizures

Mesh:

Substances:

Year:  2018        PMID: 29696750     DOI: 10.1002/ajmg.a.38694

Source DB:  PubMed          Journal:  Am J Med Genet A        ISSN: 1552-4825            Impact factor:   2.802


  8 in total

1.  Behavioral Evaluation of Angelman Syndrome Mice at Older Ages.

Authors:  Rebecca Dutta; Jacqueline N Crawley
Journal:  Neuroscience       Date:  2019-11-12       Impact factor: 3.590

2.  Anxiety in Angelman Syndrome.

Authors:  Stacey C Grebe; Danica L Limon; Morgan M McNeel; Andrew Guzick; Sarika U Peters; Wen-Hann Tan; Anjali Sadhwani; Carlos A Bacino; Lynne M Bird; Rodney C Samaco; Leandra N Berry; Wayne K Goodman; Sophie C Schneider; Eric A Storch
Journal:  Am J Intellect Dev Disabil       Date:  2022-01-01

Review 3.  Genomic Copy Number Variations in the Autism Clinic-Work in Progress.

Authors:  Milen Velinov
Journal:  Front Cell Neurosci       Date:  2019-02-19       Impact factor: 5.505

4.  Multi-Method Assessment of Sleep in Children With Angelman Syndrome: A Case-Controlled Study.

Authors:  Jayne Trickett; Chris Oliver; Mary Heald; Hayley Denyer; Andrew Surtees; Emma Clarkson; Paul Gringras; Caroline Richards
Journal:  Front Psychiatry       Date:  2019-11-29       Impact factor: 4.157

5.  An observational study of pediatric healthcare burden in Angelman syndrome: results from a real-world study.

Authors:  Nasreen Khan; Raquel Cabo; Wen-Hann Tan; Regina Tayag; Lynne M Bird
Journal:  Orphanet J Rare Dis       Date:  2019-11-04       Impact factor: 4.123

6.  A novel UBE3A sequence variant identified in eight related individuals with neurodevelopmental delay, results in a phenotype which does not match the clinical criteria of Angelman syndrome.

Authors:  Amber Geerts-Haages; Stijn N V Bossuyt; Inge den Besten; Hennie Bruggenwirth; Ineke van der Burgt; Helger G Yntema; A Mattijs Punt; Alice Brooks; Ype Elgersma; Ben Distel; Marlies Valstar
Journal:  Mol Genet Genomic Med       Date:  2020-09-05       Impact factor: 2.183

7.  The STARS Phase 2 Study: A Randomized Controlled Trial of Gaboxadol in Angelman Syndrome.

Authors:  Lynne M Bird; Cesar Ochoa-Lubinoff; Wen-Hann Tan; Gali Heimer; Raun D Melmed; Amit Rakhit; Jeannie Visootsak; Matthew J During; Christina Holcroft; Rebecca D Burdine; Alexander Kolevzon; Ronald L Thibert
Journal:  Neurology       Date:  2020-12-21       Impact factor: 9.910

Review 8.  A multidisciplinary approach and consensus statement to establish standards of care for Angelman syndrome.

Authors:  Jessica Duis; Mark Nespeca; Jane Summers; Lynne Bird; Karen G C B Bindels-de Heus; M J Valstar; Marie-Claire Y de Wit; C Navis; Maartje Ten Hooven-Radstaake; Bianca M van Iperen-Kolk; Susan Ernst; Melina Dendrinos; Terry Katz; Gloria Diaz-Medina; Akshat Katyayan; Srishti Nangia; Ronald Thibert; Daniel Glaze; Christopher Keary; Karine Pelc; Nicole Simon; Anjali Sadhwani; Helen Heussler; Anne Wheeler; Caroline Woeber; Margaret DeRamus; Amy Thomas; Emily Kertcher; Lauren DeValk; Kristen Kalemeris; Kara Arps; Carol Baym; Nicole Harris; John P Gorham; Brenda L Bohnsack; Reid C Chambers; Sarah Harris; Henry G Chambers; Katherine Okoniewski; Elizabeth R Jalazo; Allyson Berent; Carlos A Bacino; Charles Williams; Anne Anderson
Journal:  Mol Genet Genomic Med       Date:  2022-02-11       Impact factor: 2.183

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.